Land: Irland
Sprache: Englisch
Quelle: HPRA (Health Products Regulatory Authority)
MYCOPLASMA HYOPNEUMONIAE STRAIN P-5722-3
Elanco Animal Health, Eli Lilly and Company Limited
QI09AB13
MYCOPLASMA HYOPNEUMONIAE STRAIN P-5722-3
Unknown
Emulsion for Injection
POM
Porcine
Mycoplasma vaccine
Immunological
Authorised
2011-01-07
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT STELLAMUNE MYCOPLASMA 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2 ml dose contains ACTIVE SUBSTANCE Inactivated _Mycoplasma hyopneumoniae_ at least 10,529 RU* at release to ensure 6000 RU* throughout shelf-life. * = Relative ELISA Units ADJUVANTS Liquid paraffin 0.09 ml EXCIPIENTS Thiomersal 0.185 mg For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Emulsion for injection 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Fattening pigs from one week of age. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For active immunisation of fattening pigs to reduce lung lesion scores caused by _Mycoplasma hyopneumoniae_ infection. Protection against _Mycoplasma hyopneumoniae _reduces the impact of secondary bacterial infection with _Pasteurella multocida_, offering improved health and economic benefits. Immunity is acquired two weeks following the second vaccination and protection lasts throughout the fattening period. 4.3 CONTRAINDICATIONS The use of immunosuppressant drugs or procedures is contraindicated within one month of vaccination. HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 11/05/2015_ _CRN 7020780_ _page number: 1_ 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Vaccinate only healthy animals. In any animal population, a small number of individuals may fail to respond fully to vaccination. Since Stellamune Mycoplasma is only recommended for reduction of lung lesions scores caused by _Mycoplasma_ _hyopneumoniae _infection it is important that all animals in a herd should be vaccinated to reduce the spread of the disease. Use of the vaccine should be combined with high management standards to maxi Lesen Sie das vollständige Dokument